Angiotensin Converting Enzyme (ACE) Gene I/D Polymorphism Is Significantly Associated with Insulin Resistance and Polycystic Ovary Syndrome: A Meta-Analysis

Gynecologic and Obstetric Investigation

Li J.a,b· Lin Z.b· Wang S.b· Shi Q.a,c

Author affiliations

aState Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China
bThe Reproductive Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
cSchool of Public Health, Chongqing Medical University, Chongqing, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Received: September 04, 2022
Accepted: February 27, 2023
Published online: March 24, 2023

Number of Print Pages: 11
Number of Figures: 4
Number of Tables: 4

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI

Abstract

Introduction: This study was performed to clarify the effects of angiotensin converting enzyme (ACE) I/D polymorphism on the risk of insulin resistance and polycystic ovary syndrome (PCOS). Methods: Six genotype models and the mean difference (MD)/standardized mean difference (SMD) were applied to evaluate the effects of ACE I/D polymorphism on insulin resistance and PCOS risk. Results: Thirteen studies with 3,212 PCOS patients and 2,314 controls were collected. In the pooled analysis and Caucasian subgroup, the ACE I/D polymorphism was significantly associated with PCOS risk, even after removing the non-Hardy-Weinberg equilibrium (HWE) studies. Moreover, the positive effect of ACE I/D polymorphism in PCOS was mainly presented in Caucasians (removing non-HWE, DD + DI vs. II: odds ratio [OR] = 2.15, p = 0.017; DD vs. DI + II: OR = 2.64, p = 0.007; DD vs. DI: OR = 2.48, p = 0.014; DD vs. II: OR = 3.31, p = 0.005; D vs. I: OR = 2.02, p = 0.005) compared to Asians. Interestingly, only in Asians was the ACE I/D polymorphism significantly correlated to insulin levels (DI vs. II: SMD = 0.19, 95% CI = (0.03, 0.35), p = 0.023) and HOMA-IR (DI vs. II: MD = 0.50, 95% CI = (0.05, 0.95), p = 0.031). Conclusions: The D allele of the ACE I/D polymorphism promotes PCOS development. Moreover, the ACE I/D polymorphism was also associated with insulin-resistant PCOS, especially among Asians.

© 2023 S. Karger AG, Basel

References Barthelmess EK, Naz RK. Polycystic ovary syndrome current status and future perspective. Front Biosci. 2014;6(1):104–19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15. Kazemi M, Pierson RA, Lujan ME, Chilibeck PD, McBreairty LE, Gordon JJ, et al. Comprehensive evaluation of type 2 diabetes and cardiovascular disease risk profiles in reproductive-age women with polycystic ovary syndrome: a large Canadian cohort. J Obstet Gynaecol Can. 2019;41(10):1453–60. Kyrkou G, Trakakis E, Attilakos A, Panagopoulos P, Chrelias C, Papadimitriou A, et al. Metabolic syndrome in Greek women with polycystic ovary syndrome: prevalence, characteristics and associations with body mass index. A prospective controlled study. Arch Gynecol Obstet. 2016;293(4):915–23. Krysiak R, Okopień B, Gdula-Dymek A, Herman ZS. Update on the management of polycystic ovary syndrome. Pharmacol Rep. 2006;58(5):614–25. Meczekalski B, Pérez-Roncero GR, López-Baena MT, Chedraui P, Pérez-López FR. The polycystic ovary syndrome and gynecological cancer risk. Gynecol Endocrinol. 2020;36(4):289–93. Yoshimura Y. The ovarian renin-angiotensin system in reproductive physiology. Front Neuroendocrinol. 1997;18(3):247–91. Underwood PC, Adler GK. The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep. 2013;15(1):59–70. van Sande ME, Scharpé SL, Neels HM, Van Camp KO. Distribution of angiotensin converting enzyme in human tissues. Clin Chim Acta. 1985;147(3):255–60. Nazeer K, Munawar Lone N, Sadique S, Sultan S, Zia Eupash A, Riaz S. Association of Angiotensin-Converting Enzyme gene polymorphism in Pakistani women with the atypical steroidogenesis in Polycystic ovarian syndrome: a case-control study. Saudi J Biol Sci. 2021;28(6):3483–9. Bayram B, Kılıççı C, Onlü H, Ozkurt M, Erkasap N, Yıldırım E, et al. Association of angiotensin converting enzyme (ACE) gene I/D polymorphism and polycystic ovary syndrome (PCOS). Gene. 2011;489(2):86–8. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. Ożegowska K, Bartkowiak-Wieczorek J, Bogacz A, Seremak-Mrozikiewicz A, Duleba AJ, Pawelczyk L. Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome. Gynecol Endocrinol. 2020;36(6):496–500. Cintra MTR, Balarin MAS, Tanaka SCSV, Silva VIMD, Marqui ABTD, Resende EAMRd, et al. Polycystic ovarian syndrome: rs1799752 polymorphism of ACE gene. Rev Assoc Med Bras (1992). 2018;64(11):1017–22, Ożegowska K, Bogacz A, Bartkowiak-Wieczorek J, Seremak-Mrozikiewicz A, Pawelczyk L. Association between the angiotensin converting enzyme gene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome. Mol Med Rep. 2016;14(6):5401–7. Deepika MLN, Reddy KR, Rani VU, Balakrishna N, Latha KP, Jahan P. Do ACE I/D gene polymorphism serve as a predictive marker for age at onset in PCOS?J Assist Reprod Genet. 2013;30(1):125–30. Koika V, Georgopoulos NA, Piouka A, Roupas ND, Karela A, Armeni AK, et al. Increased frequency of the DI genotype of the angiotensin-I converting enzyme and association of the II genotype with insulin resistance in polycystic ovary syndrome. Eur J Endocrinol. 2012;166(4):695–702. Karabulut A, Turgut S, Turgut G. Angiotensin converting enzyme gene insertion/deletion polymorphism in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2010;26(6):393–8. Celik O, Yesilada E, Hascalik S, Celik N, Sahin I, Keskin L, et al. Angiotensin-converting enzyme gene polymorphism and risk of insulin resistance in PCOS. Reprod Biomed Online. 2010;20(4):492–8. Sun L, Lv H, Wei W, Zhang D, Guan Y. Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. J Endocrinol Invest. 2010;33(2):77–82. Sun J, Fan H, Che Y, Cao Y, Wu X, Sun HX, et al. Association between ACE gene I/D polymorphisms and hyperandrogenism in women with polycystic ovary syndrome (PCOS) and controls. BMC Med Genet. 2009;10:64. Ma WD, Fan P, Liu HW, Liu QQ, Hu KF, Bai H, et al. Clinical study of the impact of ACE I/D gene variation on the clinical parameters of patients with polycystic ovary syndrome. Sichuan Da Xue Xue Bao Yi Xue Ban. 2021;52(5):877–82. Ramanathan B, Murugan J, Velayutham K. Pilot study on evaluation and determination of the prevalence of Polycystic Ovarian Syndrome (PCOS) associated gene markers in the South Indian population. Indian J Endocrinol Metab. 2021;25(6):551–8. Schwentner L, Wöckel A, Herr D, Wulff C. Is there a role of the local tissue RAS in the regulation of physiologic and pathophysiologic conditions in the reproductive tract?J Renin Angiotensin Aldosterone Syst. 2011;12(4):385–93. Plendl J, Neumüller C, Vollmar A, Auerbach R, Sinowatz F. Isolation and characterization of endothelial cells from different organs of fetal pigs. Anat Embryol. 1996;194(5):445–56. Acosta TJ, Berisha B, Ozawa T, Sato K, Schams D, Miyamoto A. Evidence for a local endothelin-angiotensin-atrial natriuretic peptide systemin bovine mature follicles in vitro: effects on steroid hormones and prostaglandin secretion. Biol Reprod. 1999;61(6):1419–25. Stefanello JR, Barreta MH, Porciuncula PM, Arruda JN, Oliveira JF, Oliveira MA, et al. Effect of angiotensin II with follicle cells and insulin-like growth factor-I or insulin on bovine oocyte maturation and embryo development. Theriogenology. 2006;66(9):2068–76. Nielsen AH, Hagemann A, Svenstrup B, Nielsen J, Poulsen K. Angiotensin II receptor density in bovine ovarian follicles relates to tissue renin and follicular size. Clin Exp Pharmacol Physiol. 1994;21(6):463–9. Yang C, Fangfang W, Jie L, Yanlong Y, Jie W, Xuefei L, et al. Angiotensin-converting enzyme insertion/deletion (I/D) polymorphisms and recurrent pregnancy loss: a meta-analysis. J Assist Reprod Genet. 2012;29(11):1167–73. Gintoni I, Adamopoulou M, Yapijakis C. The angiotensin-converting enzyme insertion/deletion polymorphism as a common risk factor for major pregnancy complications. In Vivo. 2021;35(1):95–103. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86(4):1343–6. Jia H, Wang B, Yu L, Jiang Z. Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with polycystic ovary syndrome: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2013;14(3):255–62. Moghetti P. Insulin resistance and polycystic ovary syndrome. Curr Pharm Des. 2016;22(36):5526–34. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(4):E628–37. Tejpal S, Wemyss AM, Bastie CC, Klein-Seetharaman J. Lemon extract reduces angiotensin converting enzyme (ACE) expression and activity and increases insulin sensitivity and lipolysis in mouse adipocytes. Nutrients. 2020;12(8):2348. Son M, Chan CB, Wu J. Egg white ovotransferrin-derived ACE inhibitory peptide ameliorates angiotensin II-stimulated insulin resistance in skeletal muscle cells. Mol Nutr Food Res. 2018;62(4):1700602. Article / Publication Details

Received: September 04, 2022
Accepted: February 27, 2023
Published online: March 24, 2023

Number of Print Pages: 11
Number of Figures: 4
Number of Tables: 4

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif